Pharmadrug Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LMLLF research report →
Price Chart
About the company
Pharmadrug Inc. , a Toronto-based specialty pharmaceutical firm, is dedicated to the research, development, and market introduction of controlled substances and natural therapeutics, such as psychedelics, cannabis, and other approved compounds derived from nature. The company also manages the import and supply of medical cannabis to pharmacies across Germany and the broader European Union.
- CEO
- David Kideckel
- IPO
- 2017
- Employees
- 9
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on LMLLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $660.33K
- P/E
- -0.93
- PEG
- 0.01
- P/S
- 0.00
- P/B
- -0.37
- EV/EBITDA
- -10.21
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 37.95%
- ROIC
- -77.92%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-50,202+0.0%
- Op Income
- $-225,748
- Net Income
- $-383,064+51.7%
- EPS
- $-0.00+52.6%
- OCF Growth
- +88.4%
- FCF Growth
- +88.6%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 0.94
- RSI (14)
- 56
- Avg Volume
- 2.05K
No earnings-call transcripts are available for LMLLF yet.
- Free Float
- 99.0%
- Shares Outstanding
- 134.21M
- Float Shares
- 132.83M
Our LMLLF coverage
Recent articles, reports, and earnings notes.
No research on LMLLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LMLLF report →PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
newsfilecorp.com · May 13
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
newsfilecorp.com · May 13
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
newsfilecorp.com · Jan 5
PharmaDrug Announces Debt Restructuring
newsfilecorp.com · Oct 31
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
newsfilecorp.com · Oct 30
PharmaDrug Inc.: Correction to News Release Dated July 30, 2025
newsfilecorp.com · Jul 30
PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.
newsfilecorp.com · Jul 30
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
newsfilecorp.com · Jun 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.